Phylex Biosciences

is a next-generation vaccine company uniquely located at
the crossroads of information technology and biotechnology.

We are developing the first booster mRNA vaccine against variants of concern of the SARS-CoV-2 coronavirus. Our vaccine is designed to protect against the post-BA.5 omicron descendants now prevalent worldwide, including the BQ.1.1 and XBB.1.5 variants, both responsible for increased transmissibility of COVID-19 and limited efficacy of current vaccines. Our vaccine is also designed to protect against viral dissemination in the brain and the associated neurological and psychological symptoms of long COVID syndrome.